News & Events

Date Title and Summary Additional Formats
Toggle Summary CRISPR Therapeutics and Vertex Announce FDA Has Lifted the Clinical Hold on the Investigational New Drug Application for CTX001 for the Treatment of Sickle Cell Disease
ZUG, Switzerland   and   BOSTON   and   CAMBRIDGE, Mass. ,   Oct. 10, 2018   (GLOBE NEWSWIRE) --   CRISPR Therapeutics  (NASDAQ:CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, and   Vertex Pharmaceuticals Incorporated   (NASDAQ:VRTX)
View HTML
Toggle Summary Vertex Appoints Reshma Kewalramani, M.D., as Chief Medical Officer
- Jeffrey Chodakewitz , M.D., to retire and serve as senior advisor through early 2019- - Dr. Kewalramani to become CMO and Executive Vice President, Global Medicines Development and Medical Affairs, on April 1, 2018 - BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX)
View HTML
Toggle Summary Merck KGaA, Darmstadt, Germany Licenses Four Oncology Research and Development Programs from Vertex
-Merck KGaA, Darmstadt, Germany licenses two promising clinical-stage programs targeting DNA damage and repair, and two novel pre-clinical programs- -Vertex receives upfront payment of $230 million plus royalties on future sales- BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated
View HTML
Toggle Summary Vertex Licenses VX-787 to Janssen Pharmaceuticals for the Treatment of Influenza
-VX-787 is an investigational medicine discovered by Vertex that is designed to directly inhibit replication of the influenza virus- BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it has entered into a licensing agreement with Janssen
View HTML
Toggle Summary Oral Selective JAK3 Inhibitor VX-509 Showed Statistically Significant Improvements in Signs and Symptoms of Rheumatoid Arthritis After 12 Weeks of Treatment in Phase 2b Study
-All doses of VX-509 showed statistically significant ACR20 and ACR50 responses compared to placebo and statistically significant improvement from baseline in DAS28 compared to placebo- -Three highest doses of VX-509: ACR20 of 58% to 68% versus 18% for placebo; statistically significant ACR70
View HTML
Toggle Summary VX-787 Showed Significant Antiviral Activity and Reduced the Severity and Duration of Influenza Symptoms in Phase 2 Challenge Study
- Treatment with highest dosing regimen of VX-787 reduced viral shedding by 94 percent versus placebo; Duration of flu symptoms were reduced by nearly half - - VX-787 is an investigational new class of medicine designed to directly inhibit replication of the influenza virus - CAMBRIDGE, Mass.
View HTML
Toggle Summary The Crohn's and Colitis Foundation of Canada and Vertex Announce Collaboration to Fund Research in Inflammatory Bowel Disease
-Unique collaboration between a biotech company, nonprofit organization and academic centres to focus on underlying biology of IBD-<br> -Collaboration complements Vertex's ongoing IBD research efforts at its Canadian research and development site-
View HTML
Toggle Summary Phase 2 Data for Selective Oral JAK3 Inhibitor VX-509 Show Significant Improvements in Signs and Symptoms of Rheumatoid Arthritis
-Data to be presented at American College of Rheumatology Annual Meeting next week- -Phase 2b study evaluating longer treatment duration for VX-509 planned for early 2012- CHICAGO --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the final results from a Phase
View HTML
Toggle Summary Vertex Announces Presentation of New Data for Oral JAK3 Inhibitor VX-509 at Annual Meeting of the American College of Rheumatology
-Final data to be presented from Phase 2 study in rheumatoid arthritis- CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that two abstracts related to its investigational oral JAK3 inhibitor, VX-509, will be presented at the 2011 Annual Meeting
View HTML
Toggle Summary Phase 2a Study of Selective Oral JAK3 Inhibitor VX-509 Showed Significant Improvements in Signs and Symptoms of Rheumatoid Arthritis
-12-week data support initiation of Phase 2b study to evaluate longer treatment duration for VX-509- CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that treatment with the investigational selective oral JAK3 inhibitor VX-509 in a Phase 2a
View HTML
Toggle Summary Vertex and Alios BioPharma Announce Exclusive Worldwide Licensing Agreement for Two Nucleotide Drug Candidates, Broadening Vertex's Efforts to Develop New Combinations of Medicines for Hepatitis C
-Vertex gains worldwide rights to two distinct nucleotide analogues, ALS-2200 and ALS-2158, that act on hepatitis C polymerase- -Collaboration provides multiple opportunities to develop new "all-oral" combination regimens- CAMBRIDGE, Mass. , &amp; SOUTH SAN FRANCISCO, Calif.
View HTML
Toggle Summary Vertex Announces Completion of Phase 2 Study of VX-765 in People with Epilepsy who did not Respond to Previous Treatment
-Results support continued development of VX-765 in people with treatment-resistant epilepsy- CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced results from a recently completed Phase 2 study of VX-765 in 60 people with treatment-resistant
View HTML
Toggle Summary Vertex's Collaborator Merck Suspends Patient Enrollment in Clinical Trials of MK-0457 (VX-680) Pending Full Analysis of Clinical Data
-- Companies continue broad program to develop investigational Aurora kinase inhibitors as novel treatments for a range of cancers -- -- Merck to initiate clinical development of VX-689 --
View HTML
Toggle Summary Vertex Pharmaceuticals Announces 2007 Business Objectives at 25th Annual JPMorgan Healthcare Conference
--PROVE program to prepare for Phase 3 initiation of telaprevir (VX-950)--<br><br> -- Expanding clinical development into important HCV sub-populations --<br><br> -- Vertex building foundation for commercialization of telaprevir --
View HTML
Toggle Summary Merck and Vertex Announce Start of Pivotal Phase 2 Clinical Trial for Investigational Aurora Kinase Inhibitor MK-0457 (VX-680) in Patients with Treatment-Resistant Forms of Advanced Leukemias
- Vertex Earns $25 Million Milestone Payment Upon Start of Patient Dosing -
View HTML
Toggle Summary Merck and Vertex Announce Phase I Results for Investigational Aurora Kinase Inhibitor MK-0457 (VX-680); Compound Showed Activity in Patients with Treatment-Resistant Forms of Advanced Leukemias and Myeloproliferative Disorders
- Additional Preclinical Combination Studies Suggest Synergistic Activity of MK-0457 and Other Kinase Inhibitors -
View HTML
Toggle Summary Vertex Pharmaceuticals Announces Initiation of Phase II Development Program for Aurora Kinase Inhibitor MK-0457 (VX-680)
- Vertex earns $10 million milestone payment -
View HTML
Toggle Summary Vertex Reports Investigational p38 MAP Kinase Inhibitor, VX-702, Meets Primary Objectives in Phase II Clinical Study in Rheumatoid Arthritis
--Vertex to Advance Clinical Program; Company Expects to Initiate Combination Study of VX-702 and Methotrexate by Mid-2006--
View HTML
Toggle Summary Vertex Pharmaceuticals Announces that VX-680 Demonstrates Effect on Clinically Relevant Biomarker in Phase I Cancer Study
- Company achieves two milestones in broad collaboration with Merck to develop VX-680 and Aurora kinase inhibitors -
View HTML
Toggle Summary Vertex and Merck Initiate Clinical Study in Hematologic Cancers with Aurora Kinase Inhibitor VX-680
Vertex and Merck Initiate Clinical Study in Hematologic Cancers with Aurora Kinase Inhibitor VX-680 Whitehouse Station, NJ and Cambridge, MA, June 17, 2005 - Merck &amp; Co., Inc. (NYSE: MRK) and Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the initiation of an additional Phase I
View HTML
Toggle Summary Vertex Pharmaceuticals Initiates Phase II Clinical Study in Rheumatoid Arthritis with Investigational Oral p38 MAP Kinase Inhibitor VX-702
Vertex Pharmaceuticals Initiates Phase II Clinical Study in Rheumatoid Arthritis with Investigational Oral p38 MAP Kinase Inhibitor VX-702 Cambridge, MA, June 10, 2005 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the initiation of dosing in a Phase II clinical study in
View HTML
Toggle Summary Vertex Pharmaceuticals Licenses VX-944 to Avalon Pharmaceuticals for Development and Commercialization in the Treatment of Cancer
Vertex Pharmaceuticals Licenses VX-944 to Avalon Pharmaceuticals for Development and Commercialization in the Treatment of Cancer Cambridge, MA, and Germantown, MD, February 15, 2005 -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Avalon Pharmaceuticals Incorporated today announced that
View HTML
Toggle Summary Vertex and Merck Announce First Clinical Study for Aurora Kinase Inhibitor, VX-680, in Solid Tumor Cancers
Vertex and Merck Announce First Clinical Study for Aurora Kinase Inhibitor, VX-680, in Solid Tumor Cancers Whitehouse Station, NJ and Cambridge, MA, January 6, 2005 -- Merck &amp; Co., Inc. (NYSE: MRK) and Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that they have begun a Phase I
View HTML
Toggle Summary Preliminary Phase IIa Data for VX-702 Demonstrate Tolerability and Reduction in C-Reactive Protein in Cardiovascular Patients
-First demonstration of CRP reduction in cardiovascular patients using an oral cytokine inhibitor-
View HTML
Toggle Summary Merck & Co., Inc. and Vertex Announce Broad Collaboration to Develop and Commercialize VX-680, a Novel Compound for the Treatment of Cancer
Merck &amp; Co., Inc. and Vertex Announce Broad Collaboration to Develop and Commercialize VX-680, a Novel Compound for the Treatment of Cancer Whitehouse Station, NJ and Cambridge, MA, June 22, 2004 -- Merck &amp; Co., Inc. (NYSE: MRK) and Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today
View HTML
Toggle Summary Vertex Researchers Report First Demonstration of Tumor Growth Suppression and Tumor Regression In Vivo with Aurora Kinase Inhibitors
- Study Published in Nature Medicine -
View HTML